



Temozolomid

Gliome » Strahlentherapie in Kombination mit » IDH Wildtyp, H3 Wildtyp, Grad 4, Glioblastom

Empfehlungen der Fachgesellschaft zum Einsatz neuer Arzneimittel

Herausgeber

DGHO Deutsche Gesellschaft für Hämatologie und
Medizinische Onkologie e.V.
Bauhofstr. 12
10117 Berlin

Geschäftsführende Vorsitzende: Prof. Dr. med. Claudia Baldus

Telefon: +49 (0)30 27 87 60 89 - 0

info@dgho.de

www.dgho.de

Ansprechpartner

Prof. Dr. med. Bernhard Wörmann
Medizinischer Leiter

Quelle

www.onkopedia.com

Die Empfehlungen der DGHO für die Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen entbinden die verantwortliche Ärztin / den verantwortlichen Arzt nicht davon, notwendige Diagnostik, Indikationen, Kontraindikationen und Dosierungen im Einzelfall zu überprüfen! Die DGHO übernimmt für Empfehlungen keine Gewähr.

Inhaltsverzeichnis

| | |
|---|--------------|
| 1 Temozolomide and RT, IDH/H3 wild type, grade 4, glioblastoma | ... 2 |
|---|--------------|

Temozolomid

Dokument: Fact Sheet

Spezifizierung: Gliome » Strahlentherapie in Kombination mit » IDH Wildtyp, H3 Wildtyp, Grad 4, Glioblastom

Stand: August 2021

1 Temozolomide and RT, IDH/H3 wild type, grade 4, glioblastoma

| Temozolomide and RT, IDH/H3 wild type, grade 4, glioblastoma | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|--|----------------------------|------------------|----------------------------|-----------------|--------------|----------------|------------|---|--|---------|-------------------|-------------|-----------------------------------|----|----|----|----|----|----|--|--|--|--|--|--|--|--|--|---|---|---|---|---|--|--|--|--|--|
| Facts | | Appraisal | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <table border="1"> <thead> <tr> <th>Parameter</th> <th>Results¹⁴</th> <th>HR¹⁵</th> <th>p value</th> </tr> </thead> <tbody> <tr> <td>OS⁵</td> <td>12.1 vs 14.6</td> <td>0.63</td> <td>p < 0.0001</td> </tr> </tbody> </table> | Parameter | Results ¹⁴ | HR ¹⁵ | p value | OS ⁵ | 12.1 vs 14.6 | 0.63 | p < 0.0001 | <table border="1"> <thead> <tr> <th>5</th> <th>4</th> <th>3b</th> <th>3a</th> <th>2c</th> <th>2b</th> <th>2a</th> <th>1b</th> <th>1a</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="background-color: black;"></td> <td></td> </tr> </tbody> </table> <table border="1"> <thead> <tr> <th>1</th> <th>2</th> <th>3</th> <th>4</th> <th>5</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table> <p> <input checked="" type="checkbox"/> curative <input type="checkbox"/> non-curative </p> | | | 5 | 4 | 3b | 3a | 2c | 2b | 2a | 1b | 1a | | | | | | | | | | 1 | 2 | 3 | 4 | 5 | | | | | |
| Parameter | Results ¹⁴ | HR ¹⁵ | p value | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| OS ⁵ | 12.1 vs 14.6 | 0.63 | p < 0.0001 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 5 | 4 | 3b | 3a | 2c | 2b | 2a | 1b | 1a | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1 | 2 | 3 | 4 | 5 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <table border="1"> <tbody> <tr> <td>Patients</td> <td>Newly diagnosed, ≤70 years</td> </tr> <tr> <td>Trial</td> <td>EORTC 22981-26981, phase 3</td> </tr> <tr> <td>Randomisation</td> <td>1 : 1</td> </tr> <tr> <td>N¹</td> <td>573</td> </tr> <tr> <td>New Therapy</td> <td>Temozolomide, concomitant and after RT</td> </tr> <tr> <td>Control</td> <td>Radiotherapy (RT)</td> </tr> <tr> <td>Publication</td> <td>DOI:10.1016/S1470-2045(09)70025-7</td> </tr> </tbody> </table> | Patients | Newly diagnosed, ≤70 years | Trial | EORTC 22981-26981, phase 3 | Randomisation | 1 : 1 | N ¹ | 573 | New Therapy | Temozolomide, concomitant and after RT | Control | Radiotherapy (RT) | Publication | DOI:10.1016/S1470-2045(09)70025-7 | | | | | | | | | | | | | | | | | | | | | | | | | |
| Patients | Newly diagnosed, ≤70 years | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Trial | EORTC 22981-26981, phase 3 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Randomisation | 1 : 1 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| N ¹ | 573 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| New Therapy | Temozolomide, concomitant and after RT | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Control | Radiotherapy (RT) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Publication | DOI:10.1016/S1470-2045(09)70025-7 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

Legende:

¹ N - number of patients

⁵ OS - overall survival in months

¹⁴ results for control, results for new therapy

¹⁵ hazard ratio for new therapy